ImmunoVaccine Inc.

(IMMVF)

By |

A Clear Path Ahead

Immunovaccine (TSX: IMV; OTCQX: IMMVF) has the potential to fundamentally transform the way we use our immune system to address a broad range of serious diseases. We continue to build value in our Company by establishing collaborations with leading biotechnology and pharmaceutical companies; advancing our programs; and seeking additional opportunities to leverage DepoVax™ in underserved markets.

We have the platform, the pipeline, and the people and partners to discover and develop novel solutions to some of healthcare’s most vexing challenges. Through our internal development activities and external collaborations, we are growing a pipeline of promising combination immunotherapies and vaccines. Our experienced management team, Board of Directors, and scientific advisors are well prepared and committed to ensure that we deliver optimal value to patients and our shareholders, across all facets of our organization.

Immunovaccine Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine’s DepoVax™ platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

DepoVax™, Our Delivery Platform that Gets the Message Through

Our DepoVax technology provides the foundation of our Company and underscores the novel benefits of our product candidates across multiple therapeutic markets. Our human immune system is bombarded with countless messages and directives at any given moment. The key, we believe, is making sure that the right directives get through, safely and efficiently, to help our body do what it is already designed to do: fight serious diseases.

The technology behind our unique DepoVax-based delivery agents can help to get the messages across, by promoting the active uptake and extending the exposure time of specific antigens to the immune system. DepoVax formulations provide a simple but elegant solution to delivering the right messages, and helping to make sure they are received and acted upon, by our immune system.

Through partnerships with pharmaceutical and biotech leaders, we are leveraging the unique capabilities of DepoVax to develop innovate therapies with potential to mobilize the power of the immune system in a more rapid, robust and sustained fashion. We work with a sense of purpose, using the best science and drug development practices to address urgent unmet medical needs in cancer and other diseases.

With three candidates already in clinical trials and several more at the precipice, we are committed to building a company that can deliver value for our shareholders, patients and communities.

DPX-Survivac: A Dual-Threat Tumor Target and Optimal Combination Therapy Enabler

Using our robust and scalable DepoVax delivery platform, we develop immunotherapeutic agents that activate and direct T cells against cancer, and complement the activity of other immuno-modulating agents. Our lead candidate, DPX-Survivac, targets the protein survivin, which is present in more than 15 types of solid tumor and hematologic cancers. In addition to being a widely recognized tumor associated antigen (TAA), survivin also plays an important role in the dysregulated cell apoptosis and metastasis that are the hallmarks of cancer. Therefore, the value of manipulating this target is twofold: it is both a cell surface marker widely expressed in, but specific to, tumor cells, as well as a cancer driving mechanism that is implicated in the proliferation of the tumor itself.

DPX-Survivac is currently being evaluated in multiple clinical trials in combination with other advanced immunotherapy agents, including checkpoint inhibitors, in collaboration with our partners Incyte Corporation and Merck. These include two triple combination trials in advanced ovarian cancer, one of our main areas of therapeutic focus. We believe that DPX-Survivac’s unique, T cell-focused mechanism of action and established clinical immunogenic track record position it as an optimal choice for expanding the utility and patient response rates to today’s most groundbreaking immunotherapies.

Broad Market Potential for DepoVax-Formulated Therapies

While our internal clinical program is focused on advancing applications of DPX-Survivac in hard-to-treat cancers, we also recognize that DepoVax has a broad range of applications across multiple therapeutic areas and potential products. We are working with partners including Dana-Farber Cancer Institute and UConn Health to leverage DepoVax in our DPX-E7 and DPX NEO programs.

Beyond the cancer market, we are focused on working with partners to deploy DepoVax formulations in those areas where its novel MOA can deliver the greatest value. We have several ongoing programs in infectious diseases related to public health threats and indications with limited if any treatment options, such as virulent malaria, the Zika virus and respiratory syncytial virus (RSV).

RSV in particular is an indication that has plagued much of our industry with its treatment complexities. Believing that a novel delivery formulation can help address some of the pitfalls associated with RSV clinical programs, we have developed our DPX-RSV candidate. In a Phase 1 clinical trial, 100 percent of healthy older adult volunteers who responded to vaccine achieved a sustained antigen-specific immune response that remained at peak one year post-vaccination with DPX-RSV; we believe that this level of response with a low-dose volume of a small peptide vaccine is groundbreaking and highlights potential of DepoVax platform.

DepoVax formulations provide a number of specific advantages over other delivery systems:

  • DepoVax can be used to safely extend exposure of the immune system to practically any antigen and adjuvant combination.
  • The safety profile and sustained immunological activity of DepoVax have been demonstrated in both preclinical studies and human clinical trials in multiple cancer and infectious disease indications.
  • DepoVax vaccines can be combined readily with other immunotherapeutic approaches, including immune modulators and checkpoint inhibitors.
  • DepoVax may require fewer administrations than currently available immunotherapies, with the potential for single-dose effectiveness in certain indications.
  • DepoVax therapies are fully synthetic and relatively easy to manufacture; each vaccine is stored in dry form and reconstituted in oil for injection, providing an extended shelf life and simple handling and administration in the clinic.

For more information on DepoVax™ please click here.

Leadership

Frederic “Fred” Ors
Chief Executive Officer

Fred has served as our Chief Executive Officer since April 2016. As CEO, he has led the transformation of Immunovaccine into a leading clinical-stage immune oncology company with world-class collaborators and a strong scientific foundation.

He has more than 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining Immunovaccine, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013.

Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a BSc degree in Biology and a Master degree in Management from the University of Angers (France).


Pierre Labbé
Chief Financial Officer

Pierre has more than 25 years of progressive financial leadership roles in various industries. Prior to joining Immunovaccine, he was Vice President and Chief Financial Officer of Leddartech Inc. His experience in the life sciences sector includes serving as Chief Financial Officer and secretary of Medicago Inc. until the completion of the privatization of Medicago Inc., following the acquisition by Mitsubushi Pharma for an enterprise value of $357M CAN in 2013. In his career as senior financial officer, he has participated in the development of strategic plans, financing and in mergers and acquisitions (over $1 billion CAN in transactions).
Pierre is also a Director of Osisko Gold Royalties Ltd and Agility Health Inc. He holds a Bachelor’s Degree in Business Administration and a license in accounting from Université Laval, Québec City. Pierre is a member of Ordre des comptables professionnels agréés du Québec, the Chartered Professional Accountants of Canada and the Institute of Corporate Directors.


Gabriela Nicola Rosu, MD
Chief Medical Officer

Gabriela brings more than 20 years of medical and pharmaceutical experience to her tenure at Immunovaccine. Prior to joining the Company, she was most recently a Medical Science Liaison for Janssen Inc., responsible for implementing the medical strategy at the regional level. Previously, she served as a Global Medical Advisor in hematology for Novo Nordisk, where she actively participated in developing the global medical strategy and clinical development plans for multiple compounds. Her duties also encompassed overseeing clinical trials’ planning and publications for early development-phase compounds, as well as regulatory filing support and post-approval commitments for late-stage candidates and marketed products.
She started her career in the pharmaceutical industry when she immigrated to Canada with her family, and has risen in ranks at companies including Berlex, Celgene, Novo Nordisk, Lundbeck, gathering extensive experience in several therapeutic areas, including hematology and oncology. Gabriela graduated from the University of Medicine an Pharmacy Gr.T. Popa in her native country, Romania. Following graduation and internship, she practiced as a family and emergency physician in Iasi, Romania, for five years.


Stephan Fiset
Vice President, Clinical Research

Stephan manages the implementation and progress of Immunovaccine’s clinical programs. Prior to joining the company, he worked for more than 15 years in clinical research with Medicago, GlaxoSmithKline and the Infectious Disease Research Center of the CHUL, where he led multifunctional teams in several therapeutic areas, including Oncology, HIV, Vaccines, Sepsis, Hematology, and Neurology. Throughout his career, he was involved in scientific and operational activities of several Phase I to Phase III trials. He has also led several process improvement teams to ensure timely and cost-effective delivery of clinical trials. Stephan received an MBA with honor from Université Laval and a Master degree in Microbiology from the University of Sherbrooke.


Leeladhar Sammatur
Vice President, Product Development & Manufacturing

Leeladhar is responsible for the chemistry, manufacturing and control operations of Immunovaccine’s DepoVax™ based vaccine candidates. He has more than 20 years of experience in vaccine product development, from conceptualization to commercialization. He joined Immunovaccine in 2007 as Head Scientist, Analytical Development and was promoted to the role of Director, Product Development in 2010. He became Vice President, Product Development & Manufacture in 2016. His work encompasses formulation and process development, production at contract sites, supply chain management and analytical development operations for the Company’s DepoVax- based investigational products. Prior to joining Immunovaccine, Leeladhar worked at GSK, Novartis, Bharat Biotech and Uni-Sankyo in various capacities.

Leeladhar is a member of the American Association of Pharmaceutical Scientists, the American Chemical Society and the Drug Information Association. He received his Master’s degree in Biochemistry from Sri Krishna Deveraya University.


Marianne Stanford, PhD
Vice President, Research

Marianne oversees all preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. She also serves as adjunct professor in Microbiology and Immunology at Dalhousie University, as a member of the Vaccine Discovery group of the Canadian Centre for Vaccinology, and as an Associate Member of the Beatrice Hunter Cancer Research Institute. Before joining the Company in 2010, Marianne conducted her postdoctoral training at the Robarts Research Institute and at the Ottawa Hospital Research Institute (OHRI), focusing her research on the use of viruses in the development of novel cancer treatments. While at the OHRI, she worked with Jennerex Biotherapeutics (now SillaJen) in the development of Pexa-Vec for human clinical trials. She received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University. In her spare time, Marianne is involved in science outreach and policy and is the former Chair of the Canadian Association of Postdoctoral Scholars.


Annie Tanguay
Senior Director, Quality


Annie is responsible for development, implementation and maintenance of Immunovaccine’s Quality systems, programs and processes to ensure GXPs compliance. She brings more than 27 years of experience in pharmaceuticals and biopharmaceuticals industries to Immunovaccine, serving over half of these years in multinational pharmaceutical companies involved in Sterile Products manufacturing. During a 10-year career at Abbott Laboratories, she served in many Quality roles with increasing responsibilities, from Quality Control (QC) laboratory supervisor to Plant Compliance Manager.

Prior to joining Immunovaccine, she spent almost 15 years at Telesta Therapeutics (formerly known as Bioniche Life Sciences), where she held the position of Quality Director at the Montreal manufacturing facility, which specialized in Sterile Biologic Manufacturing. She was responsible for development and implementation of the Quality Manufacturing Systems (QMS) at the facility, set-up of QC laboratories and overall GMP site compliance. She has actively participated in meetings with regulatory agencies (FDA and Health Canada BGTD) and has hosted several GMP inspections. She holds a BSc in Microbiology from Laval University in Quebec.


Additional Information

ImmunoVaccine Inc.

Profile

Immunovaccine is a biotechnology company focused on advancing cancer therapies and infectious disease vaccines based on its proprietary products and DepoVax™ platform

Contact Information

Website: www.imvaccine.com
Email: info@imvaccine.com
Main Phone: +1 902 492-1819
Address: 1344 Summer Street
Address 2: Suite 412
State: NS
City / Town: Halifax
Country: CAN
Postal Code: B3H 0A8

Issuer Information

Exchange: OTCQX
CEO: Frederic Ors
Employees: 26
Issuer Type: CS - Common Stock
Sector/Industry: Healthcare
NAICS: Pharmaceutical P
$ 0.95 $ -0.0145 (-1.50%)
Last Price 0.95 Change $ -0.0145 Change % -1.50 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 0.95 High 0.95 Low 0.95 Prev Close 0.97
Last Trade Volume 5,800 52 Wk Hi 1.23 52 Wk Low 0.48
Market Cap 121.7 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 127,701,209.00 EPS (TTM) N/A PE Ratio N/A Exchange OTCQX